(WGBS) Positive Results Single Cell Study Utilizing Its SmartChip(TM) Technology

Results to be Presented at Upcoming 2015 Advances in Genome Biology & Technology (AGBT) Meeting

FREMONT, Calif., Feb. 25, 2015  — WaferGen Bio-systems, (Nasdaq:WGBS) announced today that it has produced positive results in a study aimed at validating the utility of its SmartChip^TM technology for isolating and studying single cells via Next-Generation Sequencing (NGS). The study was conducted in collaboration with the Broad Institute, and the findings will be presented at the 2015 Advances in Genome Biology & Technology (AGBT) meeting to be held February 25-28 in Marco Island, Florida.

In a proof of concept study, WaferGen has engineered a solution for depositing single cells into the individual SmartChip^TM wells in a directed fashion, to achieve far greater chip utilization. At this level of efficiency, each chip could produce more than 4,000 single cells for analysis. The cell’s genetic composition was then successfully analyzed with the NGS method by adapting the Single Cell RNA Barcoding and Sequencing (SCRB-Seq) technology pioneered by the Broad Institute.  SCRB-Seq measurements have already resulted in critical discoveries of novel cell types that play an important role in disease mechanisms.

“We are pleased with the single cell transcriptome analysis results obtained with the SmartChip™ platform in this initial study,” said Dr. Chad Nusbaum, Scientific Director, Broad Technology Labs, and Co-Director, Genome Sequencing and Analysis at Broad Institute.

“Single cell analysis has the potential to play a significant role in the development of precision medicine, which is transforming healthcare,” said Ivan Trifunovich, President and Chief Executive Officer of WaferGen. “We expect our SmartChip^TM technology will be able to yield a 50-fold increase in the production of single cells per chip at a fraction of the current per cell cost. We continue to expect to launch an Early Access Program for this technology during the second quarter of 2015.”

About WaferGen

WaferGen Bio-systems, Inc. is a life science company that offers innovative genomic solutions for clinical testing and research. The SmartChip MyDesign^TM Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping. The SmartChip TE^TM System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS). The Seq-Ready^TM TE System powered by SmartChip^TM massively-parallel singleplex PCR technology, is an innovative one-step target enrichment and library preparation solution. The Company now also offers the Apollo 324^TM product line used in library preparation for NGS. These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage and our expectations concerning our competitive position and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: INVESTOR CONTACTS:

         WaferGen Bio-systems, Inc.
         Ivan Trifunovich
         ivan.trifunovich@wafergen.com
         (510) 651-4450

         LifeSci Advisors, LLC
         Brian Stollar
         bstollar@lifesciadvisors.com